关于饮食在代谢功能障碍相关脂肪性肝病中作用的误解与事实
Myths and facts about the role of diet in metabolic dysfunction-associated steatotic liver disease.
作者信息
Fernandes Sabrina Alves
机构信息
Santa Casa de Porto Alegre Hospital Complex, Porto Alegre 90020-090, Rio Grande do Sul, Brazil.
出版信息
World J Hepatol. 2025 Aug 27;17(8):107909. doi: 10.4254/wjh.v17.i8.107909.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of liver-related morbidity worldwide. Despite broad consensus on the importance of diet in managing the disease, numerous myths and misconceptions persist among patients, healthcare professionals, and the general public. This article aims to critically review the main myths and facts surrounding the role of diet in MASLD, in light of the most current scientific evidence.
摘要
代谢功能障碍相关脂肪性肝病（MASLD）已成为全球肝脏相关发病的主要原因。尽管在饮食对该疾病管理的重要性方面已达成广泛共识，但患者、医护人员和普通公众中仍存在许多误解和错误观念。本文旨在根据最新科学证据，对围绕饮食在MASLD中作用的主要误解和事实进行批判性综述。
相似文献
1
Myths and facts about the role of diet in metabolic dysfunction-associated steatotic liver disease.关于饮食在代谢功能障碍相关脂肪性肝病中作用的误解与事实
World J Hepatol. 2025 Aug 27;17(8):107909. doi: 10.4254/wjh.v17.i8.107909.
3
Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.代谢功能障碍相关脂肪性肝病与心房颤动：发病机制综述
World J Cardiol. 2025 Jun 26;17(6):106147. doi: 10.4330/wjc.v17.i6.106147.
4
Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials.地中海饮食、运动及其联合干预对代谢功能障碍相关脂肪性肝病患者身体成分和肝脏结局的影响：一项随机对照试验的系统评价和荟萃分析
BMC Med. 2025 Aug 27;23(1):502. doi: 10.1186/s12916-025-04320-7.
5
Breaking boundaries: Unraveling metabolic dysfunction-associated steatotic liver disease in children of India and Canada.突破界限：解析印度和加拿大儿童中与代谢功能障碍相关的脂肪性肝病
Can Liver J. 2024 Feb 26;7(3):327-337. doi: 10.3138/canlivj-2023-0023. eCollection 2024 Aug.
6
Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease.关于胰高血糖素样肽-1（GLP-1）治疗代谢功能障碍相关脂肪性肝病患者的通俗易懂总结。
Postgrad Med. 2025 Jul 30:1-7. doi: 10.1080/00325481.2025.2537617.
7
The Midlands Liver Research Alliance - A partnership to optimise obesity-related liver disease research: targeting areas of high incidence and underserved communities.中部地区肝脏研究联盟——优化肥胖相关肝病研究的合作伙伴关系：针对高发病地区和服务不足的社区。
NIHR Open Res. 2024 Dec 12;4:75. doi: 10.3310/nihropenres.13784.1. eCollection 2024.
8
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.糖尿病患者的代谢功能障碍相关脂肪性肝病（MASLD）：筛查与早期干预的必要性。美国糖尿病协会共识报告
Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094.
9
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review.用于管理代谢功能障碍相关脂肪性肝病的食物营养素和生物活性化合物：综述
Nutrients. 2025 Jul 3;17(13):2211. doi: 10.3390/nu17132211.
10
Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.炎症标志物作为代谢功能障碍相关脂肪性肝病的诊断和精准营养工具：来自肥胖相关性脂肪肝试验的结果。
Clin Nutr. 2024 Jul;43(7):1770-1781. doi: 10.1016/j.clnu.2024.05.042. Epub 2024 May 31.
本文引用的文献
1
Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy.日常临床实践中的非酒精性脂肪性肝病：从诊断到治疗
Life (Basel). 2025 Feb 25;15(3):363. doi: 10.3390/life15030363.
2
The effects of saturated and unsaturated fatty acids on MASLD: a Mendelian randomization analysis and in vivo experiment.饱和脂肪酸与不饱和脂肪酸对代谢相关脂肪性肝病的影响：孟德尔随机化分析及体内实验
Eur J Nutr. 2024 Dec 24;64(1):52. doi: 10.1007/s00394-024-03560-2.
3
Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.代谢功能障碍相关脂肪性肝病引起的抗氧化系统变化：综述
Arch Toxicol. 2025 Jan;99(1):1-22. doi: 10.1007/s00204-024-03889-x. Epub 2024 Oct 23.
4
Mechanisms of body fat distribution and gluteal-femoral fat protection against metabolic disorders.身体脂肪分布及臀股部脂肪对代谢紊乱的保护机制。
Front Nutr. 2024 Mar 25;11:1368966. doi: 10.3389/fnut.2024.1368966. eCollection 2024.
5
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.对于非酒精性脂肪性肝病（NAFLD）的瘦患者，代谢功能障碍相关脂肪性肝病（MASLD）的定义优于代谢功能障碍相关脂肪性肝病（MAFLD）标准。
J Hepatol. 2024 Feb;80(2):e61-e62. doi: 10.1016/j.jhep.2023.07.031. Epub 2023 Aug 7.
6
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
7
Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017-2018.美国成年人饮食质量与代谢功能障碍相关脂肪性肝病（MAFLD）的关系：NHANES 2017-2018 年的结果。
Nutrients. 2022 Oct 26;14(21):4505. doi: 10.3390/nu14214505.
8
Low fat diet versus low carbohydrate diet for management of non-alcohol fatty liver disease: A systematic review.低脂饮食与低碳水化合物饮食治疗非酒精性脂肪性肝病的系统评价
Front Nutr. 2022 Aug 16;9:987921. doi: 10.3389/fnut.2022.987921. eCollection 2022.
9
The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis.地中海饮食和热量限制对非酒精性脂肪性肝病（NAFLD）的有效性和可接受性：系统评价和荟萃分析。
Clin Nutr. 2022 Sep;41(9):1913-1931. doi: 10.1016/j.clnu.2022.06.037. Epub 2022 Jul 2.
10
Epigenetics in inflammatory liver diseases: A clinical perspective (Review).炎症性肝病中的表观遗传学：临床视角（综述）
Exp Ther Med. 2022 May;23(5):366. doi: 10.3892/etm.2022.11293. Epub 2022 Apr 4.
Zotero 插件